Cutting edge discovery and development targeting
Parkinson's disease

OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen new molecules on our proprietary human-specific minibrains which represent a model mimicking faithfully the human Parkinson’s disease pathology. OrganoTherapeutics aims at developing new drug candidates against Parkinson’s disease which are tested in state-of-the art 3D patient models. OrganoTherapeutics has developed first own proprietary drug candidates and has access to attractive libraries for further screening.

Our solution

OrganoTherapeutics is a spin-off project from the University of Luxembourg. We screen for novel compounds which can be therapeutic for different patient sub-groups.

Better Models

Minibrain models that recapitulate key features of Parkinson’s disease

New Screening

Focus of the screening approach on the reverse of the cellular defect rather than on specific pre-design targets


Development of human, personalized or sub-group stratified models


Fuel the drug discovery phase with more compounds to treat Parkinson’s disease


Target more efficiently compound candidates going to the preclinical phase -> increased success rate

Find out more

Latest news

Animal Free research UK is the leading medical charity in the UK that supports the replacement of the use of…

On September 4th, 2023, Startup Bubble news published an article featuring OrganoTherapeutics’ work. Startup Bubble is a news media platform…